Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Revenue projections:

Revenue projections for CAPLIPOINT
Revenue projections for CAPLIPOINT

With CAPLIPOINT's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 6.70000
forwardPE 23.40533
debtToEquity 0.12700
earningsGrowth 0.19400
revenueGrowth 0.19000
grossMargins 0.60420
operatingMargins 0.30898
trailingEps 84.22000
forwardEps 106.95000

CAPLIPOINT's current ratio being 6.7 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, CAPLIPOINT can easily cover its immediate liabilities, reflecting solid financial health.
Caplin Point Laboratories Limited's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
CAPLIPOINT's positive growth in earnings and revenue suggests the company is on track to expand its business. These indicators highlight a healthy financial performance, with CAPLIPOINT expected to increase its market presence and profitability.
Caplin Point Laboratories Limited's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
CAPLIPOINT's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting CAPLIPOINT to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for CAPLIPOINT
Price projections for CAPLIPOINT

The price of CAPLIPOINT has repeatedly been close to the lower limit of price projections. This trend suggests that the stock may be underperforming, raising concerns among investors about future performance.

Recommendation changes over time:

Recommendations trend for CAPLIPOINT
Recommendations trend for CAPLIPOINT


CAPLIPOINT has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view CAPLIPOINT as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.